Therefore, downregulated PES1 resulted in a delay in the development of ovarian cancer via activated ERβ but attenuated ERα, which further proposed PES1 as a therapeutic target for treatment of ovarian cancer [26], which was consistent with our findings. This evidence concerns the gene ESR1 and ovarian carcinoma.